Seeking Alpha

Andy Batts

 
View as an RSS Feed
View Andy Batts' Articles BY TICKER:
  • Update: Abbott Posted Ordinary Third Quarter Earnings
    Today, 2:22 PM ABT Comment!

    Summary

    • Abbott’s earnings excluding special items grew 12.7% to $0.62 per share in the third quarter.
    • Revenue in the quarter increased 5.8% primarily based on growth in nutrition and vision care products.
    • I continue to remain bullish on Abbott, but not as bullish as earlier.
  • Update: Abaxis Q2 FY15 Earnings
    Yesterday, 1:35 PM ABAX Comment!

    Summary

    • Abaxis reported impressive financial results for second-quarter fiscal 2015.
    • In my original article I mentioned that Abaxis' veterinary instrument division is expected to witness stable performance.
    • Its veterinary market revenue increased 20.1% year-over-year to $45.6 million during the quarter.
    • I believe the stock is heading towards $59.50, my original projected price.
  • Update: Intuitive Surgical Q3 Earnings
    Yesterday, 12:07 PM ISRG Comment!

    Summary

    • Intuitive Surgical’s profit decreased in the third quarter while sales increased.
    • Its worldwide da Vinci procedures grew nearly 10% year-over-year in the quarter.
    • I continue to remain bullish on the stock.
  • Update: TAL Education Q2 FY15 Earnings, Sell The Stock On Rallies
    Tue, Oct. 21 XRS Comment!

    Summary

    • TAL Education reported second quarter FY 2015 earnings, which overall remained in line with analysts’ expectations.
    • However, profit started to shrink with the company facing fierce competition and the Chinese economy seeing contraction.
    • I’d now recommend selling the stock on rallies.
  • Update: Johnson & Johnson Posted Impressive Q3 Earnings - Buy The Stock
    Mon, Oct. 20 JNJ 9 Comments

    Summary

    • Johnson & Johnson posted strong financial results in the third quarter of 2014, with revenue and EBITDA rising.
    • The stock corrected ~10% from the top in the last three months, as I expected.
    • Post the correction, the stock is a “Buy” as a result of strong earnings.
  • Update: Cepheid Q3 Earnings - Stock Heading Higher
    Fri, Oct. 17 CPHD 3 Comments

    Summary

    • Cepheid reported encouraging third-quarter 2014 results.
    • The company installed a total of 173 GeneXpert systems in its commercial clinical business during the quarter, and 284 additional GeneXpert systems as part of its HDBC program for tuberculosis.
    • I believe the stock is heading towards $58.60 post earnings, my medium-term target.
  • Update: Marriott Vacations Q3 Earnings
    Thu, Oct. 16 VAC Comment!

    Summary

    • Marriott Vacations posted impressive earnings for the third quarter 2014.
    • Board of Directors of the company authorized a cash dividend program.
    • In the original analysis I said Marriott Vacations enjoys significant "economies of scale" over competitors.
    • I continue to believe the stock has significant upside.
  • Update: AngioDynamics Fiscal 2015 First Quarter Earnings
    Fri, Oct. 10 ANGO Comment!

    Summary

    • AngioDynamics reported impressive financial results for the first quarter ended August 31, 2014.
    • The stock continued to remain a laggard despite the company's EBITDA margin increased 40% over the past twelve months.
    • Earnings surprises may drive the stock higher going forward.
  • Update: CalAmp Earnings - Wireless Datacom To Drive Stock Higher
    Thu, Oct. 9 CAMP 2 Comments

    Summary

    • CalAmp reported impressive earnings in the second quarter of fiscal 2015.
    • Revenue from the Wireless Datacom business was robust, as per my expectation.
    • I believe that a significant revenue expansion is imminent for the stock.
  • Update: Horsehead Reported Impressive Operations At Mooresboro Facility
    Wed, Oct. 8 ZINC 4 Comments

    Summary

    • Horsehead reported that its Mooresboro facility produced approximately 4,300 tons of zinc in the third quarter of 2014.
    • In my original article I mentioned the company was planning to construct a new $450 million zinc processing facility in Mooresboro, North Carolina.
    • After correcting almost 25% from the top, I believe the stock is again a “Buy” for long-term investors.
  • Update: Alere To Sell Health Management Business
    Wed, Oct. 8 ALR Comment!

    Summary

    • Alere is planning to sell its health management business.
    • A deal could come as soon as in the next few weeks.
    • I reiterate my “Buy” rating on the stock based on the recent news flow.
  • Update: Thoratec Appointed D. Keith Grossman President And CEO Again
    Mon, Sep. 29 THOR Comment!

    Summary

    • Thoratec announced that D. Keith Grossman has been appointed president and CEO effective immediately.
    • In my original article I mentioned that Thoratec has tremendous growth prospects in the LVAD market, although I advised to wait on the sidelines after second quarter earnings.
    • I believe that Mr. Grossman can turn the company around. The news reinstates my bull thesis on the company.
  • Update: Cynosure Received FDA Clearance For PicoSure
    Mon, Sep. 29 CYNO 1 Comment

    Summary

    • Cynosure bagged FDA 510(k) clearance to market PicoSure for the treatment of wrinkles with its new FOCUS lens array.
    • In my original article, I said that since PicoSure is picosecond-oriented, it is more effective than nanosecond-based devices.
    • The approval augments my investment thesis on the company.
  • Update: Intuitive Surgical Received FDA Approval For Its Robotics Platform
    Thu, Sep. 25 ISRG 5 Comments

    Summary

    • Intuitive Surgical has received FDA approval for its da Vinci S and da Vinci Si Surgical Systems for using in benign, base of tongue resection procedures.
    • The company has stopped using its EndoWrist Stapler 45 instrument for the da Vinci Si System.
    • In my original article I said the company's da Vinci robotic surgical platform has tremendous potential in minimally invasive procedures.
    • The FDA approval news confirms my opinion.
  • Update: Integra LifeSciences To Acquire Medtronic's Assets
    Fri, Sep. 19 IART Comment!

    Summary

    • Integra will acquire Medtronic's MicroFrance and Xomed manual ENT and laparoscopy instrumentation lines.
    • In my original article I said that Integra is a world leader of medical devices that limit uncertainty for surgeons.
    • The news confirms and strengthens my long-term investment thesis on Integra.
  • Update: Abiomed Announces Clinical Trial Results For Impella RP
    Fri, Sep. 19 ABMD 2 Comments

    Summary

    • Abiomed announced RECOVER RIGHT clinical trial results for Impella RP earlier this week.
    • In my original article I mentioned that Abiomed started enrolling patients for the RECOVER RIGHT clinical trial.
    • The result remained promising for the treatment of RVF patients, which confirms my bull thesis on Abiomed.
  • Update: Oncolytics Announced Data From Phase II Study, Shares Plummeted
    Thu, Sep. 18 ONCY 14 Comments

    Summary

    • Oncolytics announced overall and KRAS-mutated patient data from its Phase II pancreatic cancer study.
    • In my original analysis I said that REOLYSIN is expected to work on some of the most prevalent forms of cancer.
    • Although the study missed the primary endpoint, I feel this is in the price of the stock. For a development-stage company, volatility in stock price is not unusual.
  • Update: Auxilium Could Be Acquired By Endo, What Shareholders Should Do Now
    Thu, Sep. 18 AUXL 1 Comment

    Summary

    • Endo International offered a proposal to takeover Auxilium Pharmaceuticals.
    • In my original article I said that Auxilium was dirt-cheap at $17-18.
    • The takeover bid confirms my investment thesis.
  • Update: Abbott To Invest $60 Million In An Intraocular Lens Plant In Malaysia
    Mon, Sep. 15 ABT Comment!

    Summary

    • Abbott said that it will invest $60 million in an intraocular lens manufacturing plant in Malaysia.
    • In my original article I said that Abbott will enjoy the first mover advantage with its implantable Tecnis lenses in the vision care market.
    • The news and the fact that Abbott’s growth in the cataract segment outpaced global market growth confirm my view.
  • Update: CalAmp Announced CalAmp Appstore And CalAmp Connect
    Wed, Sep. 10 CAMP 2 Comments

    Summary

    • CalAmp announced CalAmp Appstore and CalAmp Connect, in order to make customers’ experience more satisfactory.
    • In my original article I mentioned that CalAmp offers its customers an extensive portfolio of communication devices along with its cloud services platform.
    • The recent announcements by the company will further strengthen its device and service portfolio.
  • Update: Cepheid Received CE-IVD Mark For Xpert TV Test
    Wed, Sep. 3 CPHD 2 Comments

    Summary

    • Cepheid just received CE-IVD mark for its Xpert TV molecular test for identifying Trichomoniasis infections in both men and women.
    • The test will run on Cepheid's GeneXpert System, the world’s leading molecular diagnostic platform.
    • I said in my original article that Cepheid has a broad range of tests that runs on its GeneXpert System.
  • Update: Johnson & Johnson Facing New Lawsuits On Pinnacle Hips
    Wed, Sep. 3 JNJ 2 Comments

    Summary

    • Johnson & Johnson is facing a new round of lawsuits over its DePuy unit’s Pinnacle line of metal-on-metal hip implants blamed for poisoning patients.
    • In the original article I mentioned that DePuy Synthes recalled its metal-on-metal hip implants.
    • As I said earlier, I believe that any near-term weakness in Johnson & Johnson will be a good investing opportunity for long-term investors.
  • Update: Johnson & Johnson Received FDA's Class I Label For Jaw-Stabilizing Device
    Tue, Sep. 2 JNJ 3 Comments

    Summary

    • The FDA has put its highest-risk Class I label on the recall of Johnson & Johnson's subsidiary DePuy Synthes' jaw stabilizing system.
    • In my original article I mentioned that the reputation of DePuy Synthes has been trashed.
    • The recent action by the FDA is expected to keep Johnson & Johnson's stock under pressure for some time.
    • Any weakness in the stock offers nice investing opportunity for the longer term, as I said earlier.
  • Update: CalAmp's Agreement With Masternaut Strengthens Its Position In Europe
    Wed, Aug. 27 CAMP 2 Comments

    Summary

    • CalAmp announced that it has expanded its supply agreement with Masternaut, Europe's leading MRM services company.
    • In the original analysis I said that CalAmp's revenue could grow at a CAGR of 20% driven by international sales, particularly Europe.
    • CalAmp’s supply agreement expansion with Masternaut confirms my bullish outlook for CalAmp.
  • Update: BioSpecifics Announces Positive XIAFLEX Data For Cellulite
    Wed, Aug. 27 BSTC 1 Comment

    Summary

    • BioSpecifics announced positive, statistically significant results from a Phase 2a study involving XIAFLEX for potential treatment of cellulite.
    • Previously I shared that top-line 30-day data from Phase Ib study showed that XIAFLEX is effective, safe and well-tolerated for Cellulite.
    • The positive and statistically significant results from the Phase 2a study confirm my bullish outlook for BioSpecifics.
  • Update: Intuitive Surgical's Firefly For Xi Has Been Approved By The FDA
    Wed, Aug. 27 ISRG 3 Comments

    Summary

    • Intuitive Surgical received FDA approval for its Firefly imaging system for its new robotic platform da Vinci Xi.
    • Although I didn’t anticipate the event when I wrote my original analysis, I believe that Firefly can boost the adoption rate of da Vinci Xi.
    • The approval confirms my investment thesis on Intuitive Surgical.
  • Update: Horsehead Raises $50 Million For Potential Acquisitions - Book Partial Profits
    Wed, Aug. 27 ZINC 8 Comments

    Summary

    • Horsehead has raised $50 million through two debt offerings, and earmarked the capital for possible acquisitions.
    • In my original article, I said that Horsehead, a producer and seller of zinc and nickel-based products, could give you excellent returns in a relatively short span of time.
    • Although I'm still bullish on the stock in the long run, I believe that it's time to book at least half of your profits following the debt offerings.
  • Update: Cynosure's PicoSure System Bags FDA Approval
    Tue, Aug. 26 CYNO 3 Comments

    Summary

    • Cynosure obtained FDA clearance for the PicoSure system to treat acne scars.
    • I noted in my original article that Cynosure launched PicoSure in the U.S. for tattoo removal, although I didn’t anticipate that it would be approved for acne scars.
    • I said that the company’s PicoSure and PrecisionTx will drive significant revenues; PicoSure approval confirms my view.
  • Update: Quantum Acquires Symform's Cloud Platform
    Tue, Aug. 26 QTM Comment!

    Summary

    • Quantum announced a few days ago that it has acquired Symform's cloud storage services platform.
    • In my original article, I said that the company has huge growth opportunities in Big Data.
    • Symform's cloud storage platform will add significant value to Quantum's Big Data business, since the platform is well-proven in the market, supporting my investment thesis.
  • Update: Myriad Genetics' Patents Are Facing Trouble Again
    Mon, Aug. 25 MYGN Comment!

    Summary

    • Genetic diagnostics lab GeneDx filed eleven petitions to invalidate patent claims held by Myriad Genetics.
    • As I noted earlier, the 2013 Supreme Court ruling declared that isolated human genes are not patentable, which significantly challenged Myriad's patent landscape.
    • Since GeneDx’s filed petitions aren’t directly related to Myriad’s myRisk Hereditary Cancer test, I continue to remain bullish on Myriad Genetics.
    • Any weakness in the stock as a result of the GeneDx news should be utilized as a buying opportunity.
  • Update: DexCom's CEO Selling Shares, Key Takeaway
    Mon, Aug. 25 DXCM 3 Comments

    Summary

    • DexCom’s CEO Terrance H. Gregg and several other insiders have been selling shares of DexCom aggressively over the past few days.
    • In my original article I said that the stock is trading at a fair valuation at $42 until there is more visibility in terms of future earnings.
    • Aggressive insider selling activity over the past few days supports my view that the stock is fully valued at the current price.
  • Abbott To Develop Portable Blood Tests For Concussions
    Thu, Aug. 21 ABT 4 Comments

    Summary

    • Abbott joined forces with the United States Department of Defense for developing portable blood tests for concussions.
    • The tests will help Abbott generate significant revenues not only from the military personnel, but also from civilian people in general.
    • Abbott's stock is relatively undervalued compared to its peers and could have significant upside.